You are here

Investor Relations

Home

Jeffrey Leiden, Chairman, President and CEO

Date	Title and Summary
Toggle SummaryApr 16, 2019	CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia ZUG, Switzerland and CAMBRIDGE and BOSTON, Mass. – April 16, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CTX001 for the General Business
Toggle SummaryApr 12, 2019	Vertex to Announce First-Quarter 2019 Financial Results on April 30 BOSTON --(BUSINESS WIRE)--Apr. 12, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2019 financial results on Tuesday, April 30, 2019 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET . Webcasts
Toggle SummaryApr 2, 2019	Vertex Appoints Charles Wagner as Chief Financial Officer BOSTON --(BUSINESS WIRE)--Apr. 2, 2019-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Charles (Charlie) Wagner as Executive Vice President and Chief Financial Officer (CFO), effective April 10, 2019 . Mr. Wagner will report directly to Vertex Chairman, General Business